SI-Bone Inc (NASDAQ:SIBN) has earned an average broker rating score of 1.00 (Strong Buy) from the four analysts that cover the company, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy rating.
Brokerages have set a 12 month consensus price target of $24.75 for the company and are forecasting that the company will post ($0.20) EPS for the current quarter, according to Zacks. Zacks has also given SI-Bone an industry rank of 69 out of 257 based on the ratings given to its competitors.
SIBN has been the subject of several recent research reports. Bank of America initiated coverage on SI-Bone in a report on Monday, November 12th. They issued a “buy” rating and a $23.00 price target for the company. Canaccord Genuity initiated coverage on SI-Bone in a report on Monday, November 12th. They issued a “buy” rating and a $25.00 price target for the company. JMP Securities initiated coverage on SI-Bone in a report on Monday, November 12th. They issued an “outperform” rating and a $27.00 price target for the company. Finally, Morgan Stanley initiated coverage on SI-Bone in a report on Monday, November 12th. They issued an “overweight” rating and a $24.00 price target for the company.
In related news, major shareholder Skyline Venture Partners V. Lp acquired 325,000 shares of the stock in a transaction dated Friday, October 19th. The shares were bought at an average cost of $15.00 per share, for a total transaction of $4,875,000.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director David P. Bonita acquired 200,000 shares of the stock in a transaction dated Friday, October 19th. The stock was bought at an average price of $15.00 per share, for a total transaction of $3,000,000.00. The disclosure for this purchase can be found here.
SI-Bone stock opened at $20.29 on Friday. SI-Bone has a 12 month low of $16.27 and a 12 month high of $21.96.
SI-Bone (NASDAQ:SIBN) last posted its quarterly earnings results on Thursday, November 29th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.03). The business had revenue of $13.38 million during the quarter. On average, sell-side analysts anticipate that SI-Bone will post -0.63 EPS for the current fiscal year.
SI-BONE, Inc, a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.
Featured Story: Book Value Of Equity Per Share – BVPS Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SI-Bone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-Bone and related companies with MarketBeat.com's FREE daily email newsletter.